Partnering & LicensingProtagen has successfully developed the proprietary UNIarray® technology platform for the development of novel, non-invasive diagnostic tests based on auto-antibody signatures in human blood. A major focus of Protagen is to out-license validated auto-antibody markers and marker panels for the diagnosis of auto-immune, neurodegenerative and malignant neoplasm disorders. At the same time, this outstanding technology position can be used to build long-term R&D partnerships with diagnostic and pharmaceutical companies to enable and accelerate clinical drug developments and improve cost-effectiveness. Protagen welcomes collaborations with partners for companion diagnostic programs and clinical studies associated with patient/disease stratification, disease progression and response to therapy monitoring testing. For more information on our partnering and licensing programs, please contact the Protagen Business Development Team: Protagen AG
|
